Six generic-drug-makers, including Mylan, Teva Pharmaceuticals and Heritage Pharmaceuticals — allegedly the “ring leader” — are accused of conspiring to fix generic-drug prices and divide market share, according to a lawsuit filed by 20 US states. The allegations involve glyburide, an older diabetes treatment, and doxycycline hyclate, a delayed-release antibiotic, the price of which rose from $20 for 500 tablets in October 2013 to $1,849 in May 2014.